Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth
S. Deshpande, M. Y. Ansari, J. Sutar, P. Das, N. Hingankar, S. Mukherjee, P. Jayal, S. Singh, A. Anantharaj, J. Singh, S. Chattopadhyay, S. Raghavan, M. Gosain, S. Chauhan, S. Shrivas, C. Prasad, S. Chauhan, N. Sharma, P. Jana, R. Thiruvengadam, P. Kshetrapal, N. Wadhwa, B. Das, G. Batra, G. R. Medigeshi, , J. Bhattacharya
Abstract
Understanding the quality of immune repertoire triggered during natural infection can provide vital clues that form the basis for development of humoral immune response in some individuals capable of broadly neutralizing pan SARS-CoV-2 variants. We assessed the diversity of neutralizing antibody responses developed in an unvaccinated individual infected with ancestral SARS-CoV-2 by examining the ability of the distinct B cell germline-derived monoclonal antibodies (mAbs) in neutralizing known and currently circulating Omicron variants by pseudovirus and authentic virus neutralization assays. The ability of the antibodies developed post vaccination in neutralizing Omicron variants was compared to that obtained at baseline of the same individual and to those obtained from Omicron breakthrough infected individuals by pseudovirus neutralization assay. Broadly SARS-CoV-2 neutralizing mAbs representing unique B cell lineages with non-overlapping epitope specificities isolated from a single donor varied in their ability to neutralize Omicron variants. Plasma antibodies developed post vaccination from this individual demonstrated neutralization of Omicron BA.1, BA.2 and BA.4 with increased magnitude and found to be comparable with those obtained from other vaccinated individuals who were infected with ancestral SARS-CoV-2. Development of B cell repertoire capable of producing antibodies with distinct affinity and specificities for the antigen immediately after infection capable of eliciting broadly neutralizing antibodies offers highest probability in protecting against evolving SARS-CoV-2 variants. ImportanceDevelopment of robust neutralizing antibodies in SARS-CoV-2 convalescent individuals is known, however varies at population level. We isolated monoclonal antibodies from an individual infected with ancestral SARS-CoV-2 in early 2020 that not only varied in their B cell lineage origin but also varied in their capability and potency to neutralize all the known VOC and currently circulating Omicron variants. This indicated establishment of unique lineages that contributed in forming B cell repertoire in this particular individual immediately following infection giving rise to diverse antibody responses that could compensate each other in providing broadly neutralizing polyclonal antibody response. Individuals who were able to produce such potent polyclonal antibody responses after infection have a higher chance of being protected from evolving SARS-CoV-2 variants.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
A. Banerjee, J. Lew, … D. Falzarano·bioRxiv·Jan 13, 2022
- Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
D. Planas, N. Saunders, … O. Schwartz·bioRxiv·Dec 14, 2021
- Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual
D. Guerra, T. Beaumont, … M. J. van Gils·iSciencePeer-reviewed·Oct 1, 2023
- A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
- B cells imprinted by ancestral SARS-CoV-2 develop pan-sarbecovirus neutralization in immune recalls
Xixian Chen, Ling Li, … Teng Zuo·bioRxiv·Oct 13, 2024
- Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
D. J. Sheward, C. Kim, … B. Murrell·bioRxiv·Dec 19, 2021